New Lows: Novogen (NASDAQ:NVGN), Zafgen Inc (NASDAQ:ZFGN), Lpath (NASDAQ:LPTN), Ambit Biosciences (NASDAQ:AMBI)

Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx Inc., on June 17, 2014 announced that the proof-of-concept pre-clinical studies were successful. Novogen and its joint venture company CanTx Inc. also gave confirmation of the potency of Intra-Peritoneal Trx-1, their experimental drug. Novogen Limited (ADR) (NASDAQ:NVGN) stock performance was -1.75% in last session and finished the day at $3.37. Traded volume was 19,720.00million shares in the last session and the average volume of the stock remained 31.92K shares. The beta of the stock remained 0.79. Novogen Limited (ADR) (NASDAQ:NVGN) insider ownership is 15.08%.

Biopharmaceutical company Zafgen, Inc. ( ZFGN ) Tuesday said it has appointed Patrick Loustau as its President. Most recently, he was the Senior Vice President for Global Commercialization (Cardiovascular & Metabolics) at Bristol-Myers Squibb Co. ( BMY ). Zafgen Inc (NASDAQ:ZFGN) dropped -1.06 percent to $18.63 Thursday on volume of 24,962.00million shares. The intra-day range of the stock was $17.87 to $18.69. Zafgen Inc (NASDAQ:ZFGN) has a market capitalization of $423.03million.

Lpath, Inc. (NASDAQ:LPTN) held its annual meeting of stockholders on June 27, 2014 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the annual meeting with the Securities and Exchange Commission on May 9, 2014 (the “Proxy Statement”).  At the close of business on April 30, 2014, the record date of the Annual Meeting, the Company had 15,568,423 shares of common stock issued and outstanding. The holders of a total of 13,648,898 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a majority of the issued and outstanding shares on the record date of the Annual Meeting.  Lpath, Inc. (NASDAQ:LPTN)’s stock on July 10, 2014 reported a decrease of -5.00% to the closing price of $3.61. Its fifty two weeks range is $3.59 -$6.70. The total market capitalization recorded $58.10million. The overall volume in the last trading session was 55,876.00million shares. In its share capital, LPTN has 15.59million outstanding shares.

Equities researchers at TheStreet initiated coverage on shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a research report issued on Wednesday. The firm set a “sell” rating on the stock. On Thursday, shares of Ambit Biosciences Corp (NASDAQ:AMBI) dropped -1.68% to close the day at $5.84. Company return on investment (ROI) is -12.20% and its monthly performance is recorded as -10.43%. Ambit Biosciences Corp (NASDAQ:AMBI) quarterly revenue growth is –


Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone